Skip to main content
Premium Trial:

Request an Annual Quote

Canada Accepts Use of Roche's Mycoplasma Detection Test

NEW YORK (GenomeWeb News) – Roche announced today that the Canadian Health Authority has accepted the use of its mycoplasma detection tool for "release testing" of one of the firm's undisclosed biological products.

It said that the PCR-based test, called MycoTool, which the US Food and Drug Administration accepted for use in December, can replace conventional mycoplasma detection assays based on culture methods and in vitro assays. Such testing methods can take as long as 28 days for results, compared to one day for MycoTool, Roche said.

Mycoplasms frequently are the causes of contamination in biopharmaceutical production, cell therapy, tissue engineering, and vaccine manufacturing, according to Roche. In a statement, Ruedi Stoffel, head of Custom Biotech for Roche, said, "Fast methods, like our new MycoTool test, will greatly enhance the efficiency, quality, and safety in the manufacturing process of pharmaceutical and biological products."

In April 2011, Roche and Lonza announced an exclusive deal for co-distribution of MycoTool.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.